Ikemoto Satoru, Hamano Shin-Ichiro, Hirata Yuko, Matsuura Ryuki, Koichihara Reiko
Division of Neurology, Saitama Children's Medical Center, 2-1 Shin-toshin, Chuou-ku, Saitama-city, Saitama 330-8777, Japan.
Department of Pediatrics, The Jikei University School of Medicine, 3-19-18 Nishi-shinbashi, Minato-ku, Tokyo 105-8471, Japan.
Epilepsy Behav Case Rep. 2019 Jan 11;11:67-69. doi: 10.1016/j.ebcr.2019.01.001. eCollection 2019.
We retrospectively investigated whether perampanel (PER) could serve as an alternative for treating drug-resistant seizures in lissencephaly. We investigated the following data: age at onset of epilepsy, age at start of PER, etiology, brain MRI findings, seizure type, seizure frequency, adverse effects, and concomitant anti-epileptic drugs. There were 5 patients with lissencephaly, including 2 with Miller-Dieker syndrome. Four out of five patients exhibited ≥ 50% seizure reduction. Myoclonic seizures disappeared in 1 patient. PER was an effective adjunctive anti-seizure drug in our series of patients with lissencephaly.
我们进行了回顾性研究，以探讨吡仑帕奈（PER）是否可作为治疗无脑回畸形所致耐药性癫痫发作的替代药物。我们调查了以下数据：癫痫发作起始年龄、开始使用PER的年龄、病因、脑部磁共振成像（MRI）结果、癫痫发作类型、发作频率、不良反应以及同时使用的抗癫痫药物。共有5例无脑回畸形患者，其中2例患有米勒-迪克尔综合征。5例患者中有4例癫痫发作减少≥50%。1例患者的肌阵挛发作消失。在我们这组无脑回畸形患者中，PER是一种有效的辅助抗癫痫药物。
